Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 120
Filtrar
Más filtros

Base de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
J Neurochem ; 160(3): 325-341, 2022 02.
Artículo en Inglés | MEDLINE | ID: mdl-34878647

RESUMEN

The nucleus accumbens (NAc) plays critical roles in emotional behaviors, including aversive learning. Aversive stimuli such as an electric foot shock increase acetylcholine (ACh) in the NAc, and muscarinic signaling appears to increase neuronal excitability and aversive learning. Muscarinic signaling inhibits the voltage-dependent potassium KCNQ current which regulates neuronal excitability, but the regulatory mechanism has not been fully elucidated. Phosphorylation of KCNQ2 at threonine 217 (T217) and its inhibitory effect on channel activity were predicted. However, whether and how muscarinic signaling phosphorylates KCNQ2 in vivo remains unclear. Here, we found that PKC directly phosphorylated KCNQ2 at T217 in vitro. Carbachol and a muscarinic M1 receptor (M1R) agonist facilitated KCNQ2 phosphorylation at T217 in NAc/striatum slices in a PKC-dependent manner. Systemic administration of the cholinesterase inhibitor donepezil, which is commonly used to treat dementia, and electric foot shock to mice induced the phosphorylation of KCNQ2 at T217 in the NAc, whereas phosphorylation was suppressed by an M1R antagonist. Conditional deletion of Kcnq2 in the NAc enhanced electric foot shock induced aversive learning. Our findings indicate that muscarinic signaling induces the phosphorylation of KCNQ2 at T217 via PKC activation for aversive learning.


Asunto(s)
Reacción de Prevención/fisiología , Canal de Potasio KCNQ2/metabolismo , Proteínas del Tejido Nervioso/metabolismo , Núcleo Accumbens/metabolismo , Sistema Nervioso Parasimpático/fisiología , Proteína Quinasa C/metabolismo , Receptores Muscarínicos/fisiología , Animales , Carbacol/farmacología , Inhibidores de la Colinesterasa/farmacología , Donepezilo/farmacología , Canal de Potasio KCNQ2/genética , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Agonistas Muscarínicos/farmacología , Antagonistas Muscarínicos/farmacología , Proteínas del Tejido Nervioso/genética , Fosforilación , Receptor Muscarínico M2/efectos de los fármacos
2.
J Neurochem ; 160(3): 342-355, 2022 02.
Artículo en Inglés | MEDLINE | ID: mdl-34878648

RESUMEN

Cholinergic transmission underlies higher brain functions such as cognition and movement. To elucidate the process whereby acetylcholine (ACh) release is maintained and regulated in the central nervous system, uptake of [3 H]choline and subsequent synthesis and release of [3 H]ACh were investigated in rat striatal segments. Incubation with [3 H]choline elicited efficient uptake via high-affinity choline transporter-1, resulting in accumulation of [3 H]choline and [3 H]ACh. However, following inhibition of ACh esterase (AChE), incubation with [3 H]choline led predominantly to the accumulation of [3 H]ACh. Electrical stimulation and KCl depolarization selectively released [3 H]ACh but not [3 H]choline. [3 H]ACh release gradually declined upon repetitive stimulation, whereas the release was reproducible under inhibition of AChE. [3 H]ACh release was abolished after treatment with vesamicol, an inhibitor of vesicular ACh transporter. These results suggest that releasable ACh is continually replenished from the cytosol to releasable pools of cholinergic vesicles to maintain cholinergic transmission. [3 H]ACh release evoked by electrical stimulation was abolished by tetrodotoxin, but that induced by KCl was largely resistant. ACh release was Ca2+ dependent and exhibited slightly different sensitivities to N- and P-type Ca2+ channel toxins (ω-conotoxin GVIA and ω-agatoxin IVA, respectively) between both stimuli. [3 H]ACh release was negatively regulated by M2 muscarinic and D2 dopaminergic receptors. The present results suggest that inhibition of AChE within cholinergic neurons and of presynaptic negative regulation of ACh release contributes to maintenance and facilitation of cholinergic transmission, providing a potentially useful clue for the development of therapies for cholinergic dysfunction-associated disorders, in addition to inhibition of synaptic cleft AChE.


Asunto(s)
Acetilcolina/biosíntesis , Neostriado/metabolismo , Acetilcolinesterasa/metabolismo , Animales , Bloqueadores de los Canales de Calcio/farmacología , Colina/metabolismo , Inhibidores de la Colinesterasa/farmacología , Estimulación Eléctrica , Masculino , Cloruro de Potasio/farmacología , Radiofármacos , Ratas , Ratas Wistar , Receptor Muscarínico M2/efectos de los fármacos , Receptor Muscarínico M2/metabolismo , Receptores de Dopamina D1/efectos de los fármacos , Receptores de Dopamina D1/metabolismo , Proteínas de Transporte Vesicular de Acetilcolina/antagonistas & inhibidores , Proteínas de Transporte Vesicular de Acetilcolina/metabolismo
3.
Clin Immunol ; 212: 108346, 2020 03.
Artículo en Inglés | MEDLINE | ID: mdl-31954803

RESUMEN

Previous studies showed that circulating autoantibodies against M2 muscarinic receptors (anti-M2R Ab) are associated with decreased cardiac parasympathetic modulation in patients with chronic Chagas disease (CD). Here we investigated whether the exposure of M2R to such antibodies could impair agonist-induced receptor activation, leading to the inhibition of associated signaling pathways. Preincubation of M2R-expressing HEK 293T cells with serum IgG fractions from chagasic patients with cardiovascular dysautonomia, followed by the addition of carbachol, resulted in the attenuation of agonist-induced Gi protein activation and arrestin-2 recruitment. These effects were not mimicked by the corresponding Fab fractions, suggesting that they occur through receptor crosslinking. IgG autoantibodies did not enhance M2R/arrestin interaction or promote M2R internalization, suggesting that their inhibitory effects are not likely a result of short-term receptor regulation. Rather, these immunoglobulins could function as negative allosteric modulators of acetylcholine-mediated responses, thereby contributing to the development of parasympathetic dysfunction in patients with CD.


Asunto(s)
Autoanticuerpos/inmunología , Enfermedades del Sistema Nervioso Autónomo/inmunología , Enfermedad de Chagas/inmunología , Receptor Muscarínico M2/inmunología , Adulto , Anciano , Regulación Alostérica , Autoanticuerpos/metabolismo , Autoanticuerpos/farmacología , Enfermedades del Sistema Nervioso Autónomo/etiología , Enfermedades del Sistema Nervioso Autónomo/metabolismo , Enfermedades del Sistema Nervioso Autónomo/fisiopatología , Carbacol/farmacología , Enfermedad de Chagas/complicaciones , Enfermedad de Chagas/metabolismo , Enfermedad de Chagas/fisiopatología , Agonistas Colinérgicos/farmacología , Femenino , Subunidades alfa de la Proteína de Unión al GTP Gi-Go/metabolismo , Subunidades alfa de la Proteína de Unión al GTP Gq-G11/metabolismo , Células HEK293 , Frecuencia Cardíaca , Humanos , Masculino , Persona de Mediana Edad , Receptor Muscarínico M2/efectos de los fármacos , Receptor Muscarínico M2/metabolismo , beta-Arrestina 1/metabolismo
4.
Neuropharmacology ; 162: 107828, 2020 01 01.
Artículo en Inglés | MEDLINE | ID: mdl-31654703

RESUMEN

Cholinergic dysfunction plays a critical role in a number of disease states, and the loss of functional muscarinic acetylcholine receptors plays a key role in disease pathogenesis. Therefore, preventing receptor downregulation would maintain functional receptor number, and be predicted to alleviate symptoms. However, the molecular mechanism(s) underlying muscarinic receptor downregulation are currently unknown. Here we demonstrate that the M2 muscarinic receptor undergoes rapid lysosomal proteolysis, and this lysosomal trafficking is facilitated by ubiquitination of the receptor. Importantly, we show that this trafficking is driven specifically by ESCRT mediated involution. Critically, we provide evidence that disruption of this process leads to a re-routing of the trafficking of the M2 receptor away from the lysosome and into recycling pathway, and eventually back to the plasma membrane. This study is the first to identify the process by which the M2 muscarinic acetylcholine receptor undergoes endocytic sorting, and critically reveals a regulatory checkpoint that represents a target to pharmacologically increase the number of functional muscarinic receptors within the central nervous system.


Asunto(s)
Complejos de Clasificación Endosomal Requeridos para el Transporte/metabolismo , Lisosomas/metabolismo , Neuronas/metabolismo , Receptor Muscarínico M2/metabolismo , Ubiquitina/metabolismo , Animales , Carbacol/farmacología , Membrana Celular/efectos de los fármacos , Membrana Celular/metabolismo , Cloroquina/farmacología , Agonistas Colinérgicos/farmacología , Regulación hacia Abajo , Complejos de Clasificación Endosomal Requeridos para el Transporte/efectos de los fármacos , Endosomas/efectos de los fármacos , Endosomas/metabolismo , Endosomas/ultraestructura , Ganglios Espinales/citología , Regulación de la Expresión Génica , Células HEK293 , Humanos , Lisosomas/efectos de los fármacos , Lisosomas/ultraestructura , Microscopía Confocal , Neuronas/efectos de los fármacos , Neuronas/ultraestructura , Transporte de Proteínas/efectos de los fármacos , Proteolisis , Ratas , Receptor Muscarínico M2/efectos de los fármacos , Receptor Muscarínico M2/genética , Transfección , Ubiquitina/efectos de los fármacos , Ubiquitinación
5.
Brain Res Bull ; 144: 14-20, 2019 01.
Artículo en Inglés | MEDLINE | ID: mdl-30391542

RESUMEN

Central cholinergic activation stimulates water intake, but also NaCl intake when the inhibitory mechanisms are blocked with injections of moxonidine (α2 adrenergic/imidazoline agonist) into the lateral parabrachial nucleus (LPBN). In the present study, we investigated the involvement of central M1 and M2 muscarinic receptors on NaCl intake induced by pilocarpine (non-selective muscarinic agonist) intraperitoneally combined with moxonidine into the LPBN or by muscimol (GABAA agonist) into the LPBN. Male Holtzman rats with stainless steel cannulas implanted bilaterally in the LPBN and in the lateral ventricle were used. Pirenzepine (M1 muscarinic antagonist, 1 nmol/1 µl) or methoctramine (M2 muscarinic antagonist, 50 nmol/1 µL) injected intracerebroventricularly (i.c.v.) reduced 0.3 M NaCl and water intake in rats treated with pilocarpine (0.1 mg/100 g of body weight) injected intraperitoneally combined with moxonidine (0.5 nmol/0.2 µL) into the LPBN. In rats treated with muscimol (0.5 nmol/0.2 µL) into the LPBN, methoctramine i.c.v. also reduced 0.3 M NaCl and water intake, however, pirenzepine produced no effect. The results suggest that M1 and M2 muscarinic receptors activate central pathways involved in the control of water and sodium intake that are under the influence of the LPBN inhibitory mechanisms.


Asunto(s)
Ingestión de Líquidos/efectos de los fármacos , Núcleos Parabraquiales/metabolismo , Receptor Muscarínico M1/metabolismo , Receptor Muscarínico M2/metabolismo , Cloruro de Sodio/metabolismo , Animales , Diaminas/farmacología , Conducta de Ingestión de Líquido/efectos de los fármacos , Imidazoles/farmacología , Masculino , Agonistas Muscarínicos/farmacología , Antagonistas Muscarínicos/farmacología , Muscimol/farmacología , Núcleos Parabraquiales/efectos de los fármacos , Pilocarpina/farmacología , Pirenzepina/farmacología , Ratas , Ratas Sprague-Dawley , Receptor Muscarínico M1/efectos de los fármacos , Receptor Muscarínico M2/efectos de los fármacos , Sodio en la Dieta
6.
Mol Pharmacol ; 94(5): 1298-1309, 2018 11.
Artículo en Inglés | MEDLINE | ID: mdl-30213802

RESUMEN

Muscarinic acetylcholine receptors (mAChRs) are exemplar models for understanding G protein-coupled receptor (GPCR) allostery, possessing a "common" allosteric site in an extracellular vestibule (ECV) for synthetic modulators including gallamine, strychnine, and brucine. In addition, there is intriguing evidence of endogenous peptides/proteins that may target this region at the M2 mAChR. A common feature of synthetic and endogenous M2 mAChR negative allosteric modulators (NAMs) is their cationic nature. Using a structure-based approach, we previously designed a mutant M2 mAChR (N410K+T423K) to specifically abrogate binding of ECV cationic modulators (Dror et al., 2013). Herein, we used this "allosteric site-impaired" receptor to investigate allosteric interactions of synthetic modulators as well as basic peptides (poly-l-arginine, endogenously produced protamine, and major basic protein). Using [3H]N-methylscopolamine equilibrium and kinetic binding and functional assays of guanosine 5'-O-[γ-thio]triphosphate [35S] binding and extracellular signal-regulated kinases 1 and 2 phosphorylation, we found modest effects of the mutations on potencies of orthosteric antagonists and an increase in the affinity of the cognate agonist, acetylcholine, likely reflecting the effect of the mutations on the access/egress of these ligands into the orthosteric pocket. More importantly, we noted a significant abrogation in affinity for all synthetic or peptidic modulators at the mutant mAChR, validating their allosteric nature. Collectively, these findings provide evidence for a hitherto-unappreciated role of endogenous cationic peptides interacting allosterically at the M2 mAChR and identify the allosteric site-impaired GPCR as a tool for validating NAM activity as well as a potential candidate for future chemogenetic strategies to understand the physiology of endogenous allosteric substances.


Asunto(s)
Colinérgicos/farmacología , Receptor Muscarínico M2/efectos de los fármacos , Sitio Alostérico , Animales , Sitios de Unión , Células CHO , Cricetulus , Cinética , Ligandos , Mutación , N-Metilescopolamina/farmacología , Receptor Muscarínico M2/genética , Receptor Muscarínico M2/metabolismo , Reproducibilidad de los Resultados
7.
Neurourol Urodyn ; 37(8): 2560-2570, 2018 11.
Artículo en Inglés | MEDLINE | ID: mdl-30252154

RESUMEN

AIMS: We explored the therapeutic potential of intragastric administration traditional Chinese medicine Glycine tomentella Hayata (I-Tiao-Gung, ITG) extract and its active component Daidzin on cyclophosphamide (CYP)-induced cystitis and bladder hyperactivity in rats. METHODS: Female Wistar rats were divided into control, CYP (200 mg/kg), CYP + ITG (1.17 g/kg/day), CYP + Daidzin (12.5 mg/kg/day), and 1 week of ITG preconditioning with CYP (ITG + CYP) groups. We determined the trans cystometrogram associated with external urethral sphincter electromyogram, and the expression of M2 and M3 muscarinic and P2 × 2 and P2 × 3 purinergic receptors by Western blot in these animals. RESULTS: ITG extract contains 1.07% of Daidzin and 0.77% of Daidzein by high-performance liquid chromatography. Daidzin was more efficient than Daidzein in scavenging H2 O2 activity by a chemiluminescence analyzer. CYP induced higher frequency, shorter intercontraction interval, lower maximal voiding pressure, lower threshold pressure, and Phase-2 emptying contraction with a depressed external urethral sphincter electromyogram activity, and hemorrhagic cystitis in the bladders. The altered parameters by CYP were significantly improved in CYP + ITG, CYP + Daidzin, and ITG + CYP groups. The P2 × 2 and P2 × 3 expressions were significantly upregulated in CYP group, but were depressed in CYP + ITG, CYP + Daidzin, and ITG + CYP groups. The M2 expression was not significantly different among these five groups. The M3 expression was significantly upregulated in CYP group, but was significantly depressed in CYP + ITG, CYP + Daidzin, and ITG + CYP groups. CONCLUSIONS: These data suggest that ITG extract through its active component Daidzin effectively improved CYP-induced cystitis by the action of restoring Phase 2 activity and inhibiting the expressions of P2 × 2, P2 × 3, and M3 receptors.


Asunto(s)
Medicamentos Herbarios Chinos/farmacología , Isoflavonas/farmacología , Vejiga Urinaria/efectos de los fármacos , Animales , Ciclofosfamida/toxicidad , Cistitis/inducido químicamente , Cistitis/fisiopatología , Electromiografía , Femenino , Ratas , Ratas Wistar , Receptor Muscarínico M2/efectos de los fármacos , Receptor Muscarínico M2/metabolismo , Receptor Muscarínico M3/efectos de los fármacos , Receptor Muscarínico M3/metabolismo , Receptores Purinérgicos P2/efectos de los fármacos , Receptores Purinérgicos P2/metabolismo , Uretra/efectos de los fármacos , Uretra/fisiopatología , Vejiga Urinaria/metabolismo , Vejiga Urinaria/fisiopatología , Vejiga Urinaria Hiperactiva/inducido químicamente , Vejiga Urinaria Hiperactiva/fisiopatología , Micción/efectos de los fármacos
8.
Biochem Biophys Res Commun ; 496(1): 101-104, 2018 01 29.
Artículo en Inglés | MEDLINE | ID: mdl-29305262

RESUMEN

The muscarinic M2 receptor (M2R) has been shown to display voltage-sensitive agonist binding, based on G protein-activated inward rectifier potassium channel (GIRK) opening and radioligand binding at different membrane voltages. A conserved aspartate in transmembrane segment (TM) II of M2R, D69, has been proposed as the voltage sensor. While a recent paper instead presented evidence of tyrosines in TMs III, VI, and VII acting as voltage sensors, these authors were not able to record GIRK channel activation by a D69N mutant M2R. In the present study, we succeeded in recording ACh-induced GIRK channel activation by this mutant at -80 and 0 mV. The acetylcholine EC50 was about 2.5-fold higher at 0 mV, a potency shift very similar to that observed at wild-type M2R, indicating that voltage sensitivity persists at the D69N mutant. Thus, our present observations corroborate the notion that D69 is not responsible for voltage sensitivity of the M2R.


Asunto(s)
Acetilcolina/administración & dosificación , Canales de Potasio Rectificados Internamente Asociados a la Proteína G/metabolismo , Potenciales de la Membrana/efectos de los fármacos , Potenciales de la Membrana/fisiología , Receptor Muscarínico M2/genética , Receptor Muscarínico M2/metabolismo , Animales , Ácido Aspártico/genética , Células Cultivadas , Secuencia Conservada , Relación Dosis-Respuesta a Droga , Mutagénesis Sitio-Dirigida , Oocitos , Mutación Puntual/genética , Receptor Muscarínico M2/efectos de los fármacos , Relación Estructura-Actividad , Xenopus laevis
9.
Mol Pain ; 13: 1744806917710779, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28474958

RESUMEN

Background: Although decanoic acid (DA) is thought to act as a muscarinic cholinergic agonist, effect of DA on nociceptive behavioral responses and the excitability of nociceptive neuronal activity under in vivo conditions remain to be determined. The aim of the present study, therefore, was to investigate whether in vivo acute administration of ointment containing DA affects the excitability of nociceptive trigeminal spinal nucleus caudalis (SpVc) neurons associated with hypoalgesia in naïve rats. Results: After local application of DA, the threshold of escape from mechanical stimulation applied to the shaved orofacial skin was significantly higher than before DA application. Vehicle treatment (without DA) had no significant effect on the escape threshold from mechanical stimulation. Extracellular single unit recordings were made from SpVc wide-dynamic range (WDR) neurons in response to orofacial non-noxious and noxious mechanical stimuli of pentobarbital-anesthetized rats. The mean firing frequency of SpVc WDR neurons in response to noxious, but not non-noxious, mechanical stimuli was inhibited by local application of DA, and the maximum inhibition of discharge frequency of both non-noxious and noxious mechanical stimuli was seen within 1­5 min. The DA-induced short-term inhibitory effects were reversed after approximately 10 min. Pretreatment intravenously with the muscarinic-specific M2 receptor antagonist, methoctramine, abolished the DA-induced suppression of firing frequency of SpVc WDR neurons in response to noxious stimulation. Fluorogold (FG) labeling was identified as the trigeminal ganglion (TG) neurons innervating orofacial skin. FG-labeled small-diameter TG neurons expressed M2 receptor immunoreactivity. Conclusion: These results suggest that acute DA application induces short-term mechanical hypoalgesia and this effect was mainly due to suppression of the excitability of SpVc WDR neurons via the peripheral M2 receptor signaling pathway in the trigeminal primary afferents. These findings support the idea that DA is a potential therapeutic agent and complementary alternative medicine for the attenuation of trigeminal nociception in the absence of inflammatory/neuropathic conditions.


Asunto(s)
Ácidos Decanoicos/farmacología , Nociceptores/efectos de los fármacos , Receptor Muscarínico M2/efectos de los fármacos , Transducción de Señal/efectos de los fármacos , Potenciales de Acción/efectos de los fármacos , Alimentación Animal , Animales , Masculino , Ratas Wistar , Ganglio del Trigémino/efectos de los fármacos , Núcleo Espinal del Trigémino/citología
10.
J Cardiovasc Pharmacol ; 69(6): 369-373, 2017 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-28328743

RESUMEN

Atropine (ATr) is well known as a cholinergic antagonist, however, at low concentrations ATr could paradoxically accentuate the parasympathetic actions of acetylcholine (ACh). In 22 pentobarbital anesthetized dogs, via a left and right thoracotomy, a leak-proof barrier was attached to isolate the atrial appendages (AAs) from the rest of the atria. In group 1 (Ach+ATr+Ach), ACh, 100 mM, was placed on the AA followed by the application of ATr, 2 mg/mL. The average atrial fibrillation (AF) duration was 17 ± 7 minutes. After ATr was applied to the AA and ACh again tested, the AF duration was markedly attenuated (2 ± 2 minutes, P < 0.05). In group 2 (ATr+Ach), ATr was initially applied to the AA followed by the application of ACh, 100 mM. There was no significant difference in AF duration (16 ± 4 minutes vs. 18 ± 2 minutes, P = NS). The inhibitory effect of ATr on induced HR reduction (electrical stimulation of the anterior right ganglionated plexi and vagal nerves) was similar between groups 1 and 2. These observations suggest that when ATr is initially administered it attaches to the allosteric site of the muscarinic ACh receptor (M2) leaving the orthosteric site free to be occupied by ACh. The M3 receptor that controls HR slowing does not show the same allosteric properties.


Asunto(s)
Acetilcolina/farmacología , Antiarrítmicos/farmacología , Apéndice Atrial/efectos de los fármacos , Fibrilación Atrial/tratamiento farmacológico , Atropina/farmacología , Agonistas Colinérgicos/farmacología , Frecuencia Cardíaca/efectos de los fármacos , Antagonistas Muscarínicos/farmacología , Acetilcolina/metabolismo , Animales , Antiarrítmicos/metabolismo , Apéndice Atrial/metabolismo , Apéndice Atrial/fisiopatología , Fibrilación Atrial/etiología , Fibrilación Atrial/metabolismo , Fibrilación Atrial/fisiopatología , Atropina/metabolismo , Sitios de Unión , Estimulación Cardíaca Artificial , Agonistas Colinérgicos/metabolismo , Modelos Animales de Enfermedad , Perros , Relación Dosis-Respuesta a Droga , Interacciones Farmacológicas , Antagonistas Muscarínicos/metabolismo , Unión Proteica , Receptor Muscarínico M2/efectos de los fármacos , Receptor Muscarínico M2/metabolismo , Factores de Tiempo
11.
BMC Gastroenterol ; 17(1): 21, 2017 Jan 26.
Artículo en Inglés | MEDLINE | ID: mdl-28122499

RESUMEN

BACKGROUND: Uridine (Urd), which has been reported as a major component of RNA, plays an important role in various biological process including neuroprotection, biochemical modulation and glycolysis, although its role in constipation has yet to be established. Therefore, in this study, we investigated the laxative effects of Urd on chronic constipation. METHODS: The constipation phenotypes and their related mechanisms were investigated in the transverse colons of SD rats with loperamide (Lop)-induced constipation after treatment with 100 mg/kg of Urd. RESULTS: The number, weight and water contents of stools were significantly higher in the Lop + Urd treated group than the Lop + Vehicle treated group, while food intake and water consumption of the same group were maintained at a constant level. The thickness of the mucosa layer, muscle and flat luminal surface, as well as the number of goblet cells, paneth cells and lipid droplets were enhanced in the Lop + Urd treated group. Furthermore, the expression of the muscarinic acetylcholine receptors M2 and M3 (mAChR M2 and M3) at the transcriptional and translational level was recovered in the Lop + Urd treated group, while some markers such as Gα and inositol triphosphate (IP3) in their downstream signaling pathway were completely recovered by Urd treatment. Moreover, the ability for mucin secretion and the expression of membrane water channel (aquaporine 8, AQP8) were increased significantly in the Lop + Urd treated group compared with Lop + Vehicle treated group. Finally, the activity of Urd was confirmed in primary smooth muscle of rat intestine cells (pRISMC) based on Gα expression and IP3 concentration. CONCLUSIONS: The results of the present study provide the first strong evidence that Urd can be considered an important candidate for improving chronic constipation induced by Lop treatment in animal models.


Asunto(s)
Estreñimiento/tratamiento farmacológico , Estreñimiento/metabolismo , Laxativos/uso terapéutico , Mucinas/metabolismo , Receptor Muscarínico M2/metabolismo , Receptor Muscarínico M3/metabolismo , Uridina/uso terapéutico , Animales , Colon Transverso/efectos de los fármacos , Colon Transverso/patología , Colon Transverso/ultraestructura , Modelos Animales de Enfermedad , Conducta Alimentaria/efectos de los fármacos , Fosfatos de Inositol/metabolismo , Mucosa Intestinal/metabolismo , Mucinas/efectos de los fármacos , Músculo Liso/metabolismo , Ratas Sprague-Dawley , Receptor Muscarínico M2/efectos de los fármacos , Receptor Muscarínico M3/efectos de los fármacos , Transducción de Señal , Uridina/metabolismo , Uridina/farmacología
12.
J Neurosci ; 35(50): 16418-30, 2015 Dec 16.
Artículo en Inglés | MEDLINE | ID: mdl-26674867

RESUMEN

Neuropathic pain is one of the most debilitating pain conditions, yet no therapeutic strategy has been really effective for its treatment. Hence, a better understanding of its pathophysiological mechanisms is necessary to identify new pharmacological targets. Here, we report important metabolic variations in brain areas involved in pain processing in a rat model of oxaliplatin-induced neuropathy using HRMAS (1)H-NMR spectroscopy. An increased concentration of choline has been evidenced in the posterior insular cortex (pIC) of neuropathic animal, which was significantly correlated with animals' pain thresholds. The screening of 34 genes mRNA involved in the pIC cholinergic system showed an increased expression of the high-affinity choline transporter and especially the muscarinic M2 receptors, which was confirmed by Western blot analysis in oxaliplatin-treated rats and the spared nerve injury model (SNI). Furthermore, pharmacological activation of M2 receptors in the pIC using oxotremorine completely reversed oxaliplatin-induced mechanical allodynia. Consistently, systemic treatment with donepezil, a centrally active acetylcholinesterase inhibitor, prevented and reversed oxaliplatin-induced cold and mechanical allodynia as well as social interaction impairment. Intracerebral microdialysis revealed a lower level of acetylcholine in the pIC of oxaliplatin-treated rats, which was significantly increased by donepezil. Finally, the analgesic effect of donepezil was markedly reduced by a microinjection of the M2 antagonist, methoctramine, within the pIC, in both oxaliplatin-treated rats and spared nerve injury rats. These findings highlight the crucial role of cortical cholinergic neurotransmission as a critical mechanism of neuropathic pain, and suggest that targeting insular M2 receptors using central cholinomimetics could be used for neuropathic pain treatment. SIGNIFICANCE STATEMENT: Our study describes a decrease in cholinergic neurotransmission in the posterior insular cortex in neuropathic pain condition and the involvement of M2 receptors. Targeting these cortical muscarinic M2 receptors using central cholinomimetics could be an effective therapy for neuropathic pain treatment.


Asunto(s)
Analgésicos/farmacología , Corteza Cerebral/fisiopatología , Inhibidores de la Colinesterasa/farmacología , Indanos/farmacología , Neuralgia/fisiopatología , Sistema Nervioso Parasimpático/fisiopatología , Piperidinas/farmacología , Receptor Muscarínico M2/efectos de los fármacos , Transmisión Sináptica , Animales , Donepezilo , Expresión Génica/genética , Hiperalgesia/inducido químicamente , Hiperalgesia/tratamiento farmacológico , Relaciones Interpersonales , Masculino , Proteínas de Transporte de Membrana/metabolismo , Antagonistas Muscarínicos/farmacología , Neuralgia/inducido químicamente , Neuralgia/psicología , Compuestos Organoplatinos , Oxaliplatino , ARN Mensajero/biosíntesis , ARN Mensajero/genética , Ratas , Ratas Sprague-Dawley , Receptor Muscarínico M2/genética
13.
Am J Psychiatry ; 172(11): 1131-40, 2015 Nov 01.
Artículo en Inglés | MEDLINE | ID: mdl-26238605

RESUMEN

OBJECTIVE: Gene expression dysregulation in the brain has been associated with bipolar disorder through candidate gene and microarray expression studies, but questions remain about isoform-specific dysregulation and the role of noncoding RNAs whose importance in the brain has been suggested recently but not yet characterized for bipolar disorder. METHOD: The authors used RNA sequencing, a powerful technique that captures the complexity of gene expression, in postmortem tissue from the anterior cingulate cortex from 13 bipolar disorder case subjects and 13 matched comparison subjects. Differential expression was computed, and a global pattern of downregulation was detected, with 10 transcripts significant at a false discovery rate ≤5%. Importantly, all 10 genes were also replicated in an independent RNA sequencing data set (N=61) from the anterior cingulate cortex. RESULTS: Among the most significant results were genes coding for class A G protein-coupled receptors: SSTR2 (somatostatin receptor 2), CHRM2 (cholinergic receptor, muscarinic 2), and RXFP1 (relaxin/insulin-like family peptide receptor 1). A gene ontology analysis of the entire set of differentially expressed genes pointed to an overrepresentation of genes involved in G protein-coupled receptor regulation. The top genes were followed up by querying the effect of treatment with mood stabilizers commonly prescribed in bipolar disorder, which showed that these drugs modulate expression of the candidate genes. CONCLUSIONS: By using RNA sequencing in the postmortem bipolar disorder brain, an interesting profile of G protein-coupled receptor dysregulation was identified, several new bipolar disorder genes were indicated, and the noncoding transcriptome in bipolar disorder was characterized. These findings have important implications with regard to fine-tuning our understanding of the bipolar disorder brain, as well as for identifying potential new drug target pathways.


Asunto(s)
Trastorno Bipolar/genética , Regulación de la Expresión Génica/genética , Giro del Cíngulo/metabolismo , ARN Mensajero/metabolismo , Receptor Muscarínico M2/genética , Receptores Acoplados a Proteínas G/genética , Receptores de Péptidos/genética , Receptores de Somatostatina/genética , Adulto , Antimaníacos/farmacología , Trastorno Bipolar/metabolismo , Carbamazepina/farmacología , Estudios de Casos y Controles , Línea Celular , Femenino , Perfilación de la Expresión Génica , Regulación de la Expresión Génica/efectos de los fármacos , Humanos , Técnicas In Vitro , Compuestos de Litio/farmacología , Masculino , Persona de Mediana Edad , Células-Madre Neurales/efectos de los fármacos , Células-Madre Neurales/metabolismo , ARN Mensajero/efectos de los fármacos , Reacción en Cadena en Tiempo Real de la Polimerasa , Receptor Muscarínico M2/efectos de los fármacos , Receptores Acoplados a Proteínas G/efectos de los fármacos , Receptores de Péptidos/efectos de los fármacos , Receptores de Somatostatina/efectos de los fármacos , Análisis de Secuencia de ARN , Ácido Valproico/farmacología
14.
Toxicol Appl Pharmacol ; 287(1): 9-16, 2015 Aug 15.
Artículo en Inglés | MEDLINE | ID: mdl-26026369

RESUMEN

Long acting inhaled muscarinic receptor antagonists, such as tiotropium, are widely used as bronchodilator therapy for chronic obstructive pulmonary disease (COPD). Although this class of compounds is generally considered to be safe and well tolerated in COPD patients the cardiovascular safety of tiotropium has recently been questioned. We describe a rat in vivo model that allows the concurrent assessment of muscarinic antagonist potency, bronchodilator efficacy and a potential for side effects, and we use this model to compare tiotropium with NVA237 (glycopyrronium bromide), a recently approved inhaled muscarinic antagonist for COPD. Anaesthetized Brown Norway rats were dosed intratracheally at 1 or 6h prior to receiving increasing doses of intravenous methacholine. Changes in airway resistance and cardiovascular function were recorded and therapeutic indices were calculated against the ED50 values for the inhibition of methacholine-induced bronchoconstriction. At both time points studied, greater therapeutic indices for hypotension and bradycardia were observed with glycopyrronium (19.5 and 28.5 fold at 1h; >200 fold at 6h) than with tiotropium (1.5 and 4.2 fold at 1h; 4.6 and 5.5 fold at 6h). Pharmacokinetic, protein plasma binding and rat muscarinic receptor binding properties for both compounds were determined and used to generate an integrated model of systemic M2 muscarinic receptor occupancy, which predicted significantly higher M2 receptor blockade at ED50 doses with tiotropium than with glycopyrronium. In our preclinical model there was an improved safety profile for glycopyrronium when compared with tiotropium.


Asunto(s)
Broncoconstricción/efectos de los fármacos , Broncodilatadores/farmacocinética , Sistema Cardiovascular/efectos de los fármacos , Glicopirrolato/farmacocinética , Antagonistas Muscarínicos/farmacocinética , Derivados de Escopolamina/farmacocinética , Resistencia de las Vías Respiratorias/efectos de los fármacos , Animales , Presión Sanguínea/efectos de los fármacos , Bradicardia/inducido químicamente , Bradicardia/fisiopatología , Pruebas de Provocación Bronquial , Broncodilatadores/administración & dosificación , Broncodilatadores/sangre , Broncodilatadores/toxicidad , Sistema Cardiovascular/fisiopatología , Glicopirrolato/administración & dosificación , Glicopirrolato/sangre , Glicopirrolato/toxicidad , Frecuencia Cardíaca/efectos de los fármacos , Hipotensión/inducido químicamente , Hipotensión/fisiopatología , Masculino , Modelos Biológicos , Antagonistas Muscarínicos/administración & dosificación , Antagonistas Muscarínicos/sangre , Antagonistas Muscarínicos/toxicidad , Unión Proteica , Ensayo de Unión Radioligante , Ratas Endogámicas BN , Receptor Muscarínico M2/efectos de los fármacos , Receptor Muscarínico M2/metabolismo , Medición de Riesgo , Derivados de Escopolamina/administración & dosificación , Derivados de Escopolamina/sangre , Derivados de Escopolamina/toxicidad , Bromuro de Tiotropio
15.
Urol J ; 11(3): 1642-7, 2014 Jul 08.
Artículo en Inglés | MEDLINE | ID: mdl-25015611

RESUMEN

PURPOSE: To locate the muscarinic (M) M2 and M3 receptors in bladder interstitial cells of Cajal (ICCs) and to determine the effects of M2 and M3 agonists on bladder ICCs. MATERIALS AND METHODS: A total of 30 adult male Sprague-Dawley rats weighing 225-250 g were used in this study. Double-labeled fluorescence of muscarinic receptors and c-kit was performed for co-localization. To evaluate the effect of muscarinic agents on the excitation of bladder ICCs, we analyzed the inward current of bladder ICCs using the whole-cell patch clamp. The effect of muscarinic agents on the carbachol-induced inward currents was evaluated with the whole-cell patch clamp. RESULTS: M2 and M3 receptors were confirmed in the stroma ICCs in rats' bladders with double-labeled immunofluorescence. Spontaneous action potential was observed in freshly isolated bladder ICCs. The carbachol-induced inward Ca2+ current in ICCs can be blocked by atropine. The M2 receptor antagonist methoctramine (1 µM) showed a weak inhibitory capability on the inward Ca2+ current [from 74.8 ± 9.6 to 63.3 ± 13.8 Pascal (pA), n = 12, P = .03]. While the M3 receptor antagonist 4-diphenyl-acetoxy-N-methyl-piperidine methiodide (4-DAMP) (1 µM) significantly inhibited the inward Ca2+ current (from 78.4 ± 11.2 to 17.3 ± 7.9 pA, n = 12, P < .001). CONCLUSION: Bladder ICCs express M2 and M3 cholinergic receptors. Most muscarinic cholinergic receptor antagonists, especially the M3 antagonists, can effectively inhibit the carbamylcholine- induced inward current of bladder ICCs.


Asunto(s)
Canales de Calcio/fisiología , Células Intersticiales de Cajal/fisiología , Receptor Muscarínico M2/fisiología , Receptor Muscarínico M3/fisiología , Potenciales de Acción , Animales , Atropina/farmacología , Canales de Calcio/efectos de los fármacos , Carbacol/farmacología , Agonistas Colinérgicos/farmacología , Diaminas/farmacología , Células Intersticiales de Cajal/química , Masculino , Antagonistas Muscarínicos/farmacología , Técnicas de Placa-Clamp , Piperidinas/farmacología , Ratas , Ratas Sprague-Dawley , Receptor Muscarínico M2/análisis , Receptor Muscarínico M2/efectos de los fármacos , Receptor Muscarínico M3/análisis , Receptor Muscarínico M3/efectos de los fármacos , Vejiga Urinaria/química , Vejiga Urinaria/fisiología
16.
Am J Respir Cell Mol Biol ; 50(3): 493-501, 2014 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-24074453

RESUMEN

Brain natriuretic peptide (BNP) relaxes airways by activating natriuretic peptide receptor-A and elevating cyclic guanosine monophosphate. BNP is more effective in passively sensitized human bronchi compared with control airways. The molecular and cellular patterns involved in this signaling are unknown. The aim of this study was to investigate the influence of BNP on airway smooth muscle (ASM) cells obtained from donors with asthma and healthy donors and to identify the mechanisms involved in BNP-mediated relaxation. The contractile response of ASM cells was microscopically assessed in vitro in the presence of 1 µM BNP or with supernatant from human bronchial epithelial (BEAS-2B) cells pretreated with 1 µM BNP. We investigated the role of muscarinic M2 receptors and inducible nitric oxide synthase (iNOS), quantified the release of acetylcholine and nitric oxide (NO), and assessed the gene/protein expression of iNOS and myosin phosphatase target subunit 1 (MYPT1). Supernatant from BEAS-2B cells treated with BNP reduced the hyperreactivity of asthmatic ASM cells by shifting the potency of histamine by 1.19-fold but had no effect in healthy ASM cells. BNP was not effective directly on ASM cells. Blocking muscarinic M2-receptors and iNOS abolished the protective role of supernatant from BEAS-2B treated with BNP. BNP stimulated the release of acetylcholine (210.7 ± 11.1%) from BEAS-2B cells that in turn increased MYPT1 and iNOS gene/protein expression and enhanced NO levels in asthmatic ASM supernatant (35.0 ± 13.0%). This study provides evidence that BNP protects against bronchial hyperresponsiveness via an interaction between respiratory epithelium and ASM in subjects with asthma.


Asunto(s)
Antiasmáticos/farmacología , Asma/tratamiento farmacológico , Hiperreactividad Bronquial/prevención & control , Broncoconstricción/efectos de los fármacos , Células Epiteliales/efectos de los fármacos , Músculo Liso/efectos de los fármacos , Miocitos del Músculo Liso/efectos de los fármacos , Péptido Natriurético Encefálico/farmacología , Mucosa Respiratoria/efectos de los fármacos , Acetilcolina/metabolismo , Asma/genética , Asma/metabolismo , Asma/fisiopatología , Hiperreactividad Bronquial/genética , Hiperreactividad Bronquial/metabolismo , Hiperreactividad Bronquial/fisiopatología , Broncoconstrictores/farmacología , Estudios de Casos y Controles , Comunicación Celular/efectos de los fármacos , Células Cultivadas , Técnicas de Cocultivo , Medios de Cultivo Condicionados/metabolismo , Relación Dosis-Respuesta a Droga , Células Epiteliales/metabolismo , Humanos , Músculo Liso/metabolismo , Músculo Liso/fisiopatología , Miocitos del Músculo Liso/metabolismo , Fosfatasa de Miosina de Cadena Ligera/genética , Fosfatasa de Miosina de Cadena Ligera/metabolismo , Óxido Nítrico/metabolismo , Óxido Nítrico Sintasa de Tipo II/genética , Óxido Nítrico Sintasa de Tipo II/metabolismo , Receptor Muscarínico M2/efectos de los fármacos , Receptor Muscarínico M2/metabolismo , Mucosa Respiratoria/metabolismo , Transducción de Señal/efectos de los fármacos
17.
Artículo en Inglés | MEDLINE | ID: mdl-22660221

RESUMEN

AIM: The present study was designed to investigate the effects of progesterone-carbachol derivative on perfusion pressure and coronary resistance in rats. An additional aim was to identify the molecular mechanisms involved. METHODS: The Langendorff model was used to measure perfusion pressure and coronary resistance changes in isolated rat heart after progesterone-carbachol derivative alone and after the following compounds; mifepristone (progesterone receptor blocker), yohimbine (α2 adreno-receptor antagonist), ICI 118,551 (selective ß2 receptor blocker), atropine (non-selective muscarinic receptor antagonist), methoctramine (antagonist of M2 receptor) and L-NAME (inhibitor of nitric oxide synthase). RESULTS: The results show that progesterone-carbachol derivative [10(-9) mM] significantly decreased perfusion pressure (P=0.005) and coronary resistance (P=0.006) in isolated rat heart. Additionally, the effect of progesterone-carbachol on perfusion pressure [10(-9) to 10(-4) mM] was only blocked in the presence of methoctramine and L-NAME. CONCLUSIONS: These data suggest that progesterone derivative exert its effect on perfusion pressure via activation of the M2 muscarinic. In addition, this phenomenon involves stimulation of nitric oxide synthase (NOS).


Asunto(s)
Presión Sanguínea/efectos de los fármacos , Carbacol/análogos & derivados , Vasos Coronarios/efectos de los fármacos , Progesterona/análogos & derivados , Receptor Muscarínico M2/efectos de los fármacos , Resistencia Vascular/efectos de los fármacos , Animales , Carbacol/farmacología , Vasos Coronarios/fisiología , Masculino , Progesterona/farmacología , Ratas
18.
World J Gastroenterol ; 20(48): 18271-83, 2014 Dec 28.
Artículo en Inglés | MEDLINE | ID: mdl-25561794

RESUMEN

AIM: To investigate the effect and mechanism of acupuncture at heterotopic acupoints on jejunal motility, particularly in pathological conditions. METHODS: Jejunal motility was assessed using a manometric balloon placed in the jejunum approximately 18-20 cm downstream from the pylorus and filled with approximately 0.1 mL warm water in anesthetized normal rats or rats with diarrhea or constipation. The heterotopic acupoints including LI11 (Quchi), ST37 (Shangjuxu), BL25 (Dachangshu), and the homotopic acupoint ST25 (Tianshu), and were stimulated for 60 s by rotating acupuncture needles right and left at a frequency of 2 Hz. To determine the type of afferent fibers mediating the regulation of jejunal motility by manual acupuncture, the ipsilateral sciatic A or C fibers of ST37 were inactivated by local application of the A-fiber selective demyelination agent cobra venom or the C fiber blocker capsaicin. Methoctramine, a selective M2 receptor antagonist, was injected intravenously to identify a specific role for M2 receptors in mediating the effect of acupuncture on jejunal motility. RESULTS: Acupuncture at heterotopic acupoints, such as LI11 and ST37, increased jejunal motility not only in normal rats, but also in rats with constipation or diarrhea. In normal rats, manual acupuncture at LI11 or ST37 enhanced jejunal pressure from 7.34 ± 0.19 cmH2O to 7.93 ± 0.20 cmH2O, an increase of 9.05% ± 0.82% (P < 0.05), and from 6.95 ± 0.14 cmH2O to 8.97 ± 0.22 cmH2O, a significant increase of 27.44% ± 1.96% (P < 0.01), respectively. In constipated rats, manual acupuncture at LI11 or ST37 increased intrajejunal pressure from 8.17 ± 0.31 cmH2O to 9.86 ± 0.36 cmH2O, an increase of 20.69% ± 2.10% (P < 0.05), and from 8.82 ± 0.28 cmH2O to 10.83 ± 0.28 cmH2O, an increase of 22.81% ± 1.46% (P < 0.05), respectively. In rats with diarrhea, MA at LI11 or ST37 increased intrajejunal pressure from 11.95 ± 0.35 cmH2O to 13.96 ± 0.39 cmH2O, an increase of 16.82% ± 2.35% (P < 0.05), and tended to increase intrajejunal pressure (from 12.42 ± 0.38 cmH2O to 13.05 ± 0.38 cmH2O, an increase of 5.07% ± 1.08%, P > 0.05), respectively. In contrast, acupuncture ST25, a homotopic acupoint, decreased not only intrajejunal pressure, but also significantly decreased frequency in normal rats and rats with constipation or diarrhea. Following demyelination of Aδ fibers, acupuncture at ST37 again augmented intrajejunal pressure to 121.48% ± 3.06% of baseline. Following capsaicin application for 24 h, acupuncture at ipsilateral ST37 increased intrajejunal pressure significantly to 106.63% ± 1.26% of basal levels when compared to measurements prior to capsaicin treatment (P < 0.05). Acupuncture at LI11, ST37, or BL25 significantly rescued methoctramine-mediated inhibition of jejunal motility amplitude from 42.83% ± 1.65% to 53.43% ± 1.95% of baseline (P < 0.05), from 45.15% ± 2.22% to 70.51% ± 2.34% of baseline (P < 0.01), and from 38.03% ± 2.34% to 70.12% ± 2.22% of baseline (P < 0.01), respectively. CONCLUSION: Acupuncture at heterotopic acupoints increases the amplitude of jejunal motility in rats. C fibers and M2 receptors predominantly and partially mediate the regulation of jejunal motility by acupuncture, respectively.


Asunto(s)
Puntos de Acupuntura , Terapia por Acupuntura/métodos , Estreñimiento/terapia , Diarrea/terapia , Motilidad Gastrointestinal , Yeyuno/fisiopatología , Animales , Capsaicina/farmacología , Estreñimiento/metabolismo , Estreñimiento/fisiopatología , Diaminas/farmacología , Diarrea/metabolismo , Diarrea/fisiopatología , Modelos Animales de Enfermedad , Venenos Elapídicos/farmacología , Yeyuno/inervación , Masculino , Antagonistas Muscarínicos/farmacología , Fibras Nerviosas Mielínicas/efectos de los fármacos , Fibras Nerviosas Amielínicas/efectos de los fármacos , Presión , Ratas Sprague-Dawley , Receptor Muscarínico M2/efectos de los fármacos , Receptor Muscarínico M2/metabolismo , Fármacos del Sistema Sensorial/farmacología , Factores de Tiempo
19.
Eur Urol ; 64(3): 502-10, 2013 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-23711542

RESUMEN

BACKGROUND: First-line pharmacotherapy for overactive bladder consists of anticholinergics. However, patient compliance is exceptionally low, which may be due to progressive loss of effectiveness. OBJECTIVE: To decipher the involved molecular mechanisms and to evaluate the effects of chronic systemic administration of anticholinergics on bladder function and on muscarinic and purinergic receptors expression in rats. DESIGN, SETTING, AND PARTICIPANTS: Female Wistar rats were implanted with an osmotic pump that chronically administered vehicle (Vehc), 0.36 mg/kg per day oxybutynin (Oxyc), or 0.19 mg/kg per day fesoterodine (Fesoc) for 28 d. INTERVENTIONS: For cystometry experiments, a small catheter was implanted in the bladder. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Urologic phenotype was evaluated by the analysis of the micturition pattern and urodynamics. Expression of muscarinic and purinergic receptors was assessed by Western blot analysis of detrusor membrane protein. Functional responses to carbachol and adenosine triphosphate (ATP) were evaluated using muscle-strip contractility experiments. RESULTS AND LIMITATIONS: The number of voided spots was transiently decreased in Oxyc rats. In Oxyc rats, the effect of an acute high dose of oxybutynin (1mg/kg intraperitoneally [IP]) on the intermicturition interval was abolished. Expression experiments revealed a decrease of muscarinic acetylcholine receptors M2 (mAChR2) and M3 (mAChR3), whereas the purinergic receptor P2X, ligand-gated ion channel, 1 (P2X1) was enhanced in Oxyc and Fesoc rats compared to Vehc rats. In concordance with the modification of the expression pattern in Oxyc rats, the force generated by carbachol and ATP in muscle-strip contractility experiments was, respectively, lower and higher. Urodynamics revealed that the effects of systemic administration of the purinergic blocker pyridoxalphosphate-6-azophenyl-2',4'-disulphonic acid (50mg/kg IP) were enhanced in Oxyc rats. As rat bladder physiology is different from that of humans, it is difficult to directly extrapolate our findings to human patients. CONCLUSIONS: Chronic administration of anticholinergics in rats induces receptor loss of efficiency and a shift from muscarinic to purinergic transmission.


Asunto(s)
Compuestos de Bencidrilo/administración & dosificación , Antagonistas Colinérgicos/administración & dosificación , Neuronas Colinérgicas/efectos de los fármacos , Ácidos Mandélicos/administración & dosificación , Purinas/metabolismo , Receptores Muscarínicos/efectos de los fármacos , Receptores Purinérgicos P2X1/efectos de los fármacos , Transmisión Sináptica/efectos de los fármacos , Vejiga Urinaria/inervación , Agentes Urológicos/administración & dosificación , Animales , Agonistas Colinérgicos/farmacología , Neuronas Colinérgicas/metabolismo , Femenino , Bombas de Infusión Implantables , Contracción Muscular/efectos de los fármacos , Agonistas del Receptor Purinérgico P2X/farmacología , Antagonistas del Receptor Purinérgico P2X/farmacología , Ratas , Ratas Wistar , Receptor Muscarínico M2/efectos de los fármacos , Receptor Muscarínico M2/metabolismo , Receptor Muscarínico M3/efectos de los fármacos , Receptor Muscarínico M3/metabolismo , Receptores Muscarínicos/metabolismo , Receptores Purinérgicos P2X1/metabolismo , Factores de Tiempo , Cateterismo Urinario , Micción/efectos de los fármacos , Urodinámica/efectos de los fármacos
20.
Urology ; 81(5): 1052-7, 2013 May.
Artículo en Inglés | MEDLINE | ID: mdl-23419459

RESUMEN

OBJECTIVE: To analyze the effect of OnabotulinumtoxinA detrusor injections on postsynaptic muscular receptors in children and adolescents with neurogenic detrusor overactivity. MATERIALS AND METHODS: A bladder augmentation became necessary in 10 children and adolescents (7 males, 3 females; median age, 12 years) who had neurogenic detrusor overactivity. Seven had previously received 1 to 8 (average 3.86) OnabotulinumtoxinA detrusor injections, but their detrusor pressure could not be maintained at tolerable levels because of low-compliance bladder. The last injection session had been completed an average of 3 months (range, 1.5-3.5 months) previously. Three patients had never received that therapy and were considered controls. On the bladder dome resections, a specific receptor analysis (muscarinic M2 and M3 and purinergic P2X1, P2X2, and P2X3) was performed with confocal immunofluorescence, and nerve fiber density was analyzed with light-microscopic 3,3'-diaminobenzidine-immunohistochemical staining. RESULTS: Receptor analysis showed a downregulation of all examined receptors after OnabotulinumtoxinA injections; the reductions in M2, M3, P2X2, and P2X3 receptors reached a significance level of P <.05 (Mann-Whitney test). The ratios of means (OnabotulinumtoxinA-to-control) were 0.26 for M2, 0.33 for M3, 0.35 for P2X1, 0.19 for P2X2, and 0.37 for P2X3. CONCLUSION: OnabotulinumtoxinA detrusor injections led to significant reductions in muscular M2, M3, P2X2, and P2X3 receptors. The reductions probably affect the generated force in the urinary bladder and could contribute to the clinically observed increase in residual urine.


Asunto(s)
Toxinas Botulínicas Tipo A/administración & dosificación , Regulación hacia Abajo , Receptor Muscarínico M2/biosíntesis , Receptor Muscarínico M3/biosíntesis , Receptores Purinérgicos P2X2/biosíntesis , Receptores Purinérgicos P2X3/biosíntesis , Vejiga Urinaria Hiperactiva/tratamiento farmacológico , Adolescente , Adulto , Niño , Relación Dosis-Respuesta a Droga , Femenino , Estudios de Seguimiento , Humanos , Inmunohistoquímica , Inyecciones , Masculino , Fármacos Neuromusculares/administración & dosificación , Estudios Prospectivos , Receptor Muscarínico M2/efectos de los fármacos , Receptor Muscarínico M3/efectos de los fármacos , Receptores Purinérgicos P2X2/efectos de los fármacos , Receptores Purinérgicos P2X3/efectos de los fármacos , Método Simple Ciego , Resultado del Tratamiento , Vejiga Urinaria Hiperactiva/metabolismo , Vejiga Urinaria Hiperactiva/fisiopatología , Urodinámica/efectos de los fármacos , Adulto Joven
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA